Literature DB >> 9753273

Brewer's yeast and Saccharomyces boulardii both attenuate Clostridium difficile-induced colonic secretion in the rat.

F Izadnia1, C T Wong, S A Kocoshis.   

Abstract

Saccharomyces boulardii (Sb), a nonpathogenic yeast, has been used to prevent recurrences of Clostridium difficile (C.diff) -associated diarrhea. A single report suggested that treatment with Saccharomyces cerevisiae (Sc), commonly called brewer's yeast (BY), facilitates treatment of persistent C.diff infection. We conducted this experiment to determine whether C.diff toxin A-induced colonic secretion in the rat is blunted by pretreatment with either Sb or BY. We employed closed cecal pouches in two groups of five adult male Sprague-Dawley rats fed with standard chow for five days prior to the experiment, another group whose water was supplemented with 20 x 10(9) colony-forming units (CFU) of Sb per day for five days, and another group whose water was supplemented with 20 x 10(9) CFU of Sc per day for five days. Cecal pouches were infused for 3 hr with one of the following: (1) normal saline alone for a control group, or (2) normal saline plus 5 microg of C.diff toxin A (for the other control group and for the two experimental groups). Water movement was measured by a nonabsorbable marker technique. Sodium movement and permeability to mannitol were also measured. Prior to the infusion, cecal contents were quantitatively cultured. In the three animals whose ceca were colonized with less than 10(6) CFU of either yeast per gram wet cecal content, toxin A-induced secretion could not be attenuated. In contrast, animals whose ceca were colonized with more than 10(6) CFU of either yeast per gram of wet cecal content showed significantly less secretion after toxin A application than those which were not fed yeast. S. cerevisiae reduced secretion by half (N = 5, P = 0.039 for water, 0.044 for sodium) and Sb by 75% (N = 4, P = 0.015 for water, 0.034 for sodium). Toxin-induced increases in permeability to [3H]mannitol from systemic circulation to cecum could not be blunted by either yeast. We conclude that rat ceca can be colonized by either organism and that both organisms reduce C.diff toxin A-mediated secretion. We speculate that both organisms might have benefit in human C.diff-associated enterocolitis. Further studies of their mechanisms of action as well as clinical trials for the prevention and treatment of human C.diff infections should be pursued.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753273     DOI: 10.1023/a:1018811331596

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease.

Authors:  H McKenzie; J Main; C R Pennington; D Parratt
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

2.  Biological activities of toxins A and B of Clostridium difficile.

Authors:  D M Lyerly; D E Lockwood; S H Richardson; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

3.  Purification and characterization of toxins A and B of Clostridium difficile.

Authors:  N M Sullivan; S Pellett; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

4.  Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii.

Authors:  C M Surawicz; L V McFarland; G Elmer; J Chinn
Journal:  Am J Gastroenterol       Date:  1989-10       Impact factor: 10.864

5.  Effect of dioctyl sodium sulfosuccinate on colonic fluid and electrolyte movement.

Authors:  M Donowitz; H J Binder
Journal:  Gastroenterology       Date:  1975-10       Impact factor: 22.682

6.  Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study.

Authors:  F Castex; G Corthier; S Jouvert; G W Elmer; F Lucas; M Bastide
Journal:  J Gen Microbiol       Date:  1990-06

Review 7.  Clostridium difficile infection.

Authors:  D H Gröschel
Journal:  Crit Rev Clin Lab Sci       Date:  1996       Impact factor: 6.250

8.  Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces.

Authors:  A Schwan; S Sjölin; U Trottestam; B Aronsson
Journal:  Scand J Infect Dis       Date:  1984

9.  Lymphocyte proliferation response to baker's yeast in Crohn's disease.

Authors:  C A Young; A Sonnenberg; E A Burns
Journal:  Digestion       Date:  1994       Impact factor: 3.216

10.  Saccharomyces cerevisiae infections in man.

Authors:  R H Eng; R Drehmel; S M Smith; E J Goldstein
Journal:  Sabouraudia       Date:  1984
View more
  5 in total

1.  Novel insights in genetic transformation of the probiotic yeast Saccharomyces boulardii.

Authors:  Bruno Douradinha; Viviane C B Reis; Matthew B Rogers; Fernando A G Torres; Jared D Evans; Ernesto T A Marques
Journal:  Bioengineered       Date:  2013-09-05       Impact factor: 3.269

2.  Saccharomyces boulardii inhibits water and electrolytes changes induced by castor oil in the rat colon.

Authors:  Philippe Girard; Yannick Pansart; Marie-Claude Coppe; Jean-Marie Gillardin
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

3.  Saccharomyces boulardii in maintenance treatment of Crohn's disease.

Authors:  M Guslandi; G Mezzi; M Sorghi; P A Testoni
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

4.  Dose-response relationship and mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhea in rats.

Authors:  Philippe Girard; Yannick Pansart; Ingrid Lorette; Jean-Marie Gillardin
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

5.  Evaluating the probiotic and therapeutic potentials of Saccharomyces cerevisiae strain (OBS2) isolated from fermented nectar of toddy palm.

Authors:  Banoth Srinivas; Ganapathiwar Swarupa Rani; Bhukya Kiran Kumar; Banoth Chandrasekhar; Kommalapati Vamsi Krishna; Tangutur Anjana Devi; Bhukya Bhima
Journal:  AMB Express       Date:  2017-01-03       Impact factor: 3.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.